Pedoman Nasional Pelayanan Kedokteran (PNPK) Tata Laksana Karsinoma Sel Hati pada Dewasa tahun 2022
1 14 downloads
|
Guideline
|
12/10/2022
|
|
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
1 2 downloads
|
AtezoBev in Intermediate HCC
|
01/10/2022
|
|
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
1 1 download
|
AtezoBev in advance HCC
|
30/09/2022
|
|
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
1 1 download
|
AtezoBev in advance HCC
|
30/09/2022
|
|
IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study
1 1 download
|
AtezoBev in advance HCC
|
30/09/2022
|
|
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
1 1 download
|
AtezoBev in advance HCC
|
30/09/2022
|
|
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240 A Randomized Double-Blind Phase III Trial
1 1 download
|
Other treatment
|
29/09/2022
|
|
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
1 1 download
|
Other treatment
|
29/09/2022
|
|
Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
1 1 download
|
Other treatment
|
29/09/2022
|
|
Sorafenib in Advanced Hepatocellular Carcinoma
1 1 download
|
Other treatment
|
29/09/2022
|
|
REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
1 1 download
|
Other treatment
|
29/09/2022
|
|
A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
1 2 downloads
|
AtezoBev in Intermediate HCC
|
29/09/2022
|
|
New treatment paradigm with systemic therapy in intermediate‑stage hepatocellular carcinoma
1 1 download
|
AtezoBev in Intermediate HCC
|
29/09/2022
|
|
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
1 1 download
|
AtezoBev in advance HCC
|
29/09/2022
|
|
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
1 1 download
|
AtezoBev in advance HCC
|
29/09/2022
|
|
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
1 2 downloads
|
AtezoBev in advance HCC
|
29/09/2022
|
|
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
1 2 downloads
|
AtezoBev in advance HCC
|
29/09/2022
|
|
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
1 1 download
|
Immunotherapy in HCC
|
29/09/2022
|
|
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
1 1 download
|
Immunotherapy in HCC
|
29/09/2022
|
|
Immune Checkpoint Inhibitors in the Treatment of HCC
1 1 download
|
Immunotherapy in HCC
|
29/09/2022
|
|